Brief: Camp4 Therapeutics Receives Authorization In The United Kingdom For Phase 1/2 Human Clinical Trial Of Cmp-002 In Patients With Syngap1-Related Disorder
10/09/2026 12:50
BRIEF-Camp4 Therapeutics Receives Authorization In The United Kingdom For Phase 1/2 Human Clinical Trial Of Cmp-002 In Patients With Syngap1-Related Disorder Sept 10 (Reuters) - CAMP4 Therapeutics Corp CAMP.O:
CAMP4 THERAPEUTICS RECEIVES AUTHORIZATION IN THE UNITED KINGDOM FOR PHASE 1/2 HUMAN CLINICAL TRIAL OF CMP-002 IN PATIENTS WITH SYNGAP1-RELATED DISORDER
CAMP4 THERAPEUTICS CORP - TO INITIATE CMP-002 CLINICAL TRIAL IN Q4 2026
CAMP4 THERAPEUTICS CORP - SUBMITS REGULATORY FILINGS IN EU FOR CMP-002 TRIAL
Source text: ID:nGNX9SC5G8
Further company coverage: CAMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CAMP4 Therapeutics
See all newsBrief: Camp4 Therapeutics Receives Authorization In The United Kingdom For Phase 1/2 Human Clinical Trial Of Cmp-002 In Patients With Syngap1-Related Disorder
Camp4 Therapeutics Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Camp4 Therapeutics Q2 Loss Per Share Misses Estimates On Non: cash derivative charge
Camp4 Therapeutics Corp Expected To Post A Loss Of 21 Cents A Share: Earnings Preview
U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation